Table 3 Baseline characteristics and treatments of hypertensive and non- hypertensive COVID-19 patients without other comorbidities
Total (n = 225) | Nonhypertension (n = 160) | Hypertension (n = 65) | P value | |
|---|---|---|---|---|
Age, years | 59 (45–68) | 54 (38–67) | 66 (56–71) | <0.001 |
Sex | – | – | – | 0.728 |
Female | 101 (44.9%) | 73 (45.6%) | 28 (43.1%) | |
Male | 124 (55.1%) | 87 (54.4%) | 37 (56.9%) | |
Signs and symptoms | ||||
Fever | 190 (84.4%) | 136 (85%) | 54 (83.1%) | 0.718 |
Cough | 143 (63.6%) | 108 (67.5%) | 35 (53.8%) | 0.054 |
Dyspnea | 113 (50.2%) | 76 (47.5%) | 37 (56.9%) | 0.200 |
Expectoration | 39 (17.3%) | 32 (20.0%) | 7 (10.8%) | 0.097 |
Muscle ache | 19 (8.4%) | 12 (7.5%) | 7 (10.8%) | 0.424 |
Diarrhea | 24 (10.7%) | 13 (8.1%) | 11 (16.9%) | 0.053 |
Headache | 2 (0.9%) | 1 (0.6%) | 1 (1.5%) | 0.495 |
Treatments and prognosis | ||||
Noninvasive mechanical ventilation | 25 (11.1%) | 16 (10.0%) | 9 (13.8%) | 0.405 |
Invasive mechanical ventilation | 22 (9.8%) | 12 (7.5%) | 10 (15.4%) | 0.071 |
ECMO | 3 (1.3%) | 1 (0.6%) | 2 (3.1%) | 0.201 |
ICU admission | 32 (14.2%) | 18 (11.3%) | 14 (21.5%) | 0.045 |
Duration of viral shedding after COVID-19 onset, days | 8.0 (6.0–12.0) | 9.0 (8.0–11.5) | 8.5 (5.0–14.0) | 0.044 |
Disease severity | – | – | – | |
Non-severe | 122 (54.2%) | 99 (61.9%) | 23 (35.4%) | |
Severe | 103 (45.8%) | 61 (38.1%) | 42 (64.6%) | <0.001 |
Death | 37 (16.4%) | 23 (14.4%) | 14 (21.5%) | 0.189 |
Hospitalization time, days | 18.00 (12.00–26.00) | 14.00 (10.25–25.25) | 13.50 (10.50–22.75) | 0.409 |
